SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio is actively trending following Saudi FDA approval for its Anktiva treatment in lung cancer, sparking widespread community discussion about its potential as a game-changing, chemotherapy-free cancer therapy and its global expansion. This news, amplified by public statements from Dr. Patrick Soon-Shiong, is driving intense speculation regarding a short squeeze amidst high market interest.

SSgA Active Trust - SPDR S&P 500 ETF Trust

SPY is trending due to renewed geopolitical uncertainty as Trump's tariff threats over Greenland escalate US-EU tensions, causing futures to dip. The community is sharply divided, with bears anticipating a significant market correction, while bulls expect a "buy the dip" scenario, recalling previous tariff-related downturns that quickly reversed.

Oasis is a layer-one blockchain built to support confidential applications at scale. It’s home to Sapphire, the world’s first private EVM network, Oasis Privacy Layer, a cross-chain privacy solution for any EVM dApp, and Runtime Offchain Logic, a framework that brings trustworthy off-chain computing, onchain. Powered by its ROSE token, Oasis leverages a unique layered architecture and native rollup support, making it ideal for use cases in AI, DeFi, DAOs, gaming, and more.

Oasis Network

Oasis Network (ROSE) is trending due to its pivotal role in privacy-preserving AI and Web3 infrastructure, notably through its Sapphire runtime which secures AI agents and decentralized applications. The community is actively discussing its strong utility and recent collaborations, with many seeing ROSE as an undervalued asset poised for significant growth in the burgeoning privacy and AI sectors.

AppLovin Corp. engages in the development and operation of a mobile marketing platform. It offers AppDiscovery, MAX, Adjust, and SparkLabs. Its software-based platform caters to mobile application developers to improve the marketing and monetization of applications. The company was founded by Andrew Karam, John Krystynak, and Adam Foroughi in 2011 and is headquartered in Palo Alto, CA.

Applovin Corp - Ordinary Shares - Class A

Applovin Corp

Applovin is experiencing heightened volatility due to a fresh short report alleging questionable business practices and broader weakness in the ad tech sector. The community is actively debating if recent price movements are fueled by market manipulation and short-selling pressure ahead of anticipated strong earnings. Many bullish investors are emphasizing the company's AI-driven growth, expanding market reach, and recent analyst upgrades, viewing current price levels as a potential buying opportunity.

Alchemy Pay

Alchemy Pay is trending due to significant developments, including its upcoming Level 1 Alchemy Chain and numerous new partnerships and Money Transmitter Licenses expanding its global fiat-crypto on-ramp services. The community is vigorously debating its potential as a payment infrastructure solution, with strong bullish sentiment driven by its enhanced utility and tokenomics.

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Network and Edge (NEX), Mobileye, Accelerated Computing Systems and Graphics (AXG), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The NEX segment offers computing system solutions from inflexible fixed-function hardware to general-purpose compute, acceleration, and networking devices running cloud native software on programmable hardware. The Mobileye segment develops driving assistance and self-driving solutions. The AXG segment provides products and technologies designed to help customers solve the toughest computational problems. Its products include CPUs for high-performance computing and GPUs targeted for a range of workloads and platforms, from gaming and content creation on client devices to delivering media and gaming in the cloud, and the most demanding high-performance computing and AI workloads on supercomputers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968 and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intel is currently trending due to buzz around a massive US government contract for its Foundry Services and increasing speculation that Apple could become a key manufacturing client. This news, coupled with recent analyst upgrades, has bulls anticipating a significant rally post-earnings, while skeptics point to potential price manipulation and a stretched valuation. The stock's performance is seen as a barometer for the future of domestic chip manufacturing and its role in the booming AI sector.

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Compute and Networking Business Unit (CNBU), Mobile Business Unit (MBU), Embedded Business Unit (EBU), and Storage Business Unit (SBU). The CNBU segment includes memory products and solutions sold into client, cloud server, enterprise, graphics, and networking markets. The MBU segment is involved in memory and storage products sold into smartphone and other mobile-device markets. The EBU segment focuses on memory and storage products sold into automotive, industrial, and consumer Markets. The SBU segment consists of SSDs and component-level solutions sold into enterprise and cloud, client, and consumer storage markets. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Micron Technology is trending due to significant insider confidence, highlighted by a director's recent share purchase, and the official groundbreaking of its $100 billion U.S. megafab. The community is actively discussing an unprecedented and sustained shortage in memory chips, especially for AI, driving strong bullish sentiment around the company's strategic expansions and HBM products. Investors are anticipating continued growth as Micron addresses escalating demand.

BlackRock Institutional Trust Company N.A. - iShares 20+ Year Treasury Bond ETF

iShares 20+ Year Treasury Bond ETF

TLT is trending amid anticipation of a Supreme Court ruling on tariffs, which could influence inflation and trade stability, alongside ongoing discussions regarding political pressure on the Federal Reserve's independence. This has created a divided community, with some viewing long-term bonds as a potential recession hedge, while others remain bearish due to persistent yield concerns and broader economic uncertainty.

Uniting the six native Japanese dog breeds. Kendu is the keeper of peace, the preserver of life, and the protector of unity. Join the pack!!

Kendu

KENDU is trending with strong community conviction, driven by its unique model as a "permissionless brand" actively building real-world products and businesses. The bullish community celebrates its relentless "IRL" efforts, including launching Kendu Spice on Amazon and developing Kendu Energy drinks and entertainment initiatives. Available across Ethereum, Solana, and Base, KENDU is seen as a long-term play with dedicated holders who believe it's establishing a new paradigm for decentralized branding.

Global X Funds - Global X DAX Germany ETF

Global X DAX Germany ETF

The Global X DAX Germany ETF is actively discussed amid ongoing US-Europe trade tensions, particularly surrounding escalating tariff threats and Europe's planned fiscal stimulus for defense and infrastructure. Community sentiment remains largely bullish, focusing on Elliott Wave technical setups that suggest continued upside potential, despite recent volatility and broader economic concerns.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

What's Going On With Redhill Biopharma Stock On Tuesday?

RedHill Biopharma shares fell after a sharp rally as investors took profits, following updates on its GI drug aimed at easing GLP-1 treatment side effects and potential FDA approval paths.read more...

RedHill's RHB-102 Progresses in Multiple GI Indications Including GLP-1 Therapy-Related GI Side Effects

RedHill's RHB-102 Progresses in Multiple GI Indications Including GLP-1 Therapy-Related GI Side Effects RedHill's RHB-102 Progresses in Multiple GI Indications Including GLP-1 Therapy-Related GI Side...

RedHill Biopharma's Positive Opaganib Results Indicate Reduction in Venetoclax Resistant Cells

RedHill Biopharma's Positive Opaganib Results Indicate Reduction in Venetoclax Resistant Cells RedHill Biopharma's Positive Opaganib Results Indicate Reduction in Venetoclax Resistant Cells PR...

RedHill Biopharma Successfully Regains Compliance with Nasdaq Stockholders' Equity Requirement

RedHill Biopharma Successfully Regains Compliance with Nasdaq Stockholders' Equity Requirement RedHill Biopharma Successfully Regains Compliance with Nasdaq Stockholders' Equity Requirement PR...

RedHill Announces $10.5 Million New York Supreme Court Judgment Win Now Final for Enforcement

RedHill Announces $10.5 Million New York Supreme Court Judgment Win Now Final for Enforcement RedHill Announces $10.5 Million New York Supreme Court Judgment Win Now Final for Enforcement PR Newswire...

RedHill Biopharma Receives Nasdaq Staff Determination Notification

RedHill Biopharma Receives Nasdaq Staff Determination Notification RedHill Biopharma Receives Nasdaq Staff Determination Notification PR Newswire TEL AVIV, Israel and RALEIGH, N.C., Oct. 22, 2025 On...

RedHill Biopharma’s&nbsp;stock recorded its best trading session in more than a year on Monday after the New York Supreme Court upheld a $10 million award in the company’s ongoing legal dispute with Kukbo.Shares of the company jumped 27.2%, to close at $2.34 on Monday, before slipping 7.1% to $2.17 in after-hours trading.The Court reaffirmed its original summary judgment ruling in favor of RedHill, dismissing Kukbo’s appeal and the entirety of its defense. It ruled that Kukbo breached both the subscription and exclusive license agreements signed with RedHill in 2021 and 2022 and that RedHill had properly fulfilled its obligations, even after Kukbo’s non-payment.The total award amounts to approximately $10 million,&nbsp;comprising the original judgment of $8.25 million and an additional $1.82 million granted in August 2025 for legal costs and expenses. Both awards carry a 9% ongoing statutory interest accrual. Kukbo retains the right to further appeal the ruling.In addition to the U.S. court ruling, RedHill also secured a court-ordered seizure of Kukbo’s assets in May 2025 from Korea’s Incheon District Court, freezing those assets following the initial $8.25 million award and preventing their disposal before judgment enforcement. In August, RedHill received an additional $1.82 million for legal expenses.On Stocktwits, retail sentiment was ‘extremely bullish’ amid a 9,900% surge in 24-hour message volume.One user stated that short sellers were likely to get squeezed, arguing that RedHill’s market capitalization of approximately $7 million was significantly below the $10 million court award and calling the stock undervalued, with a fair price between $5 and $7.<stembedurl>https://stocktwits.com/PeterTauscher/message/630386393</stembedurl>Another user reported an increase in their position, noting that several potential catalysts could drive the stock higher in the coming months.<stembedurl>https://stocktwits.com/Imatron12/message/630390832</stembedurl><a href="https://stocktwits.com/symbol/RDHL">RedHill Biopharma’s stock</a> has declined 62.3% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

RedHill Biopharma’s stock (RDHL) has declined 62.3% so far in 2025. (Photo credit: Getty Images)

RedHill Biopharma Logs Best Session In Over A Year After $10M Legal Victory — Retail Sees Bullish Triggers Ahead

The stock rallied after the New York Supreme Court reaffirmed RedHill’s $10 million award in its dispute with Kukbo.

Equity

RedHill Biopharma Ltd. engages in the development and commercialization of drugs for gastrointestinal (GI), infectious diseases, and oncology. The firm's products include Talicia, Movantik, and Aemcolo. It operates through the Commercial Operations and Research and Development segments. The Commercial Operations segment covers areas relating to commercial sales through a subsidiary in the United States. The Research and Development segment includes the study and licensing of therapeutic candidates. The company was founded by Dror Ben-Asher and Ori Shilo on August 3, 2009 and is headquartered in Tel Aviv, Israel.

RDHL
RedHill Biopharma Ltd.

Feed

News

Sentiment

Fundamentals

Info

Latest RDHL News

RDHLRedHill Biopharma Ltd.